1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia

New Zealand Medical Journal

Volumn 109, Issue 1024, 1996, Pages 224-232

  Swinburn, Boyd A ^a  

^a National Heart Foundation of New Zealand   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ARTICLE; BLOOD; HUMAN; HYPERLIPIDEMIA; NEW ZEALAND; PRACTICE GUIDELINE; RISK FACTOR;

CHOLESTEROL; HUMANS; HYPERLIPIDEMIAS; NEW ZEALAND; RISK FACTORS;

EID: 0030604595     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Mann JI, Crooke M, Fear H, et al. Guidelines for detection and management of dyslipidaemia. NZ Med J 1993; 106: 133-42.
2. Anderson KM, Wilson PWF, Odell PW, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-62.
3. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of Stroke: A risk profile from the Framingham Study. Stroke 1991; 22: 312-8.
4. Core Services Committee. Guidelines for the management of raised blood pressure in New Zealand. Wellington: Ministry of Health, 1995.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival (4S) Study. Lancet 1994; 344: 1383-9.
6. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
7. Manninen V, Tenanken L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992; 85: 37-45.
8. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-2.
9. Gould A, Rossouw J, Santanello N, Heyes J, Furberg C. Cholesterol reduction yields clinical benefit. Circulation 1995; 91: 2274-82.
10. Law MR, Thompson SG. Assessing possible hazards of reducing serum cholesterol. BMJ 1994; 308: 373-9.
11. Summary of the NCEP Adult Treatment Panel II Report. JAMA 1993; 269.
12. Reaven G. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473-86.
13. Lind T. Clinical chemistry of pregnancy. Adv Clin Chem 1981; 21: 3-24.
14. Cooper G, Myers G, Smith S, Schlant R. Blood lipid measurements: variations and practical utility. JAMA 1992; 267: 1652-60.
15. Ryder RE, Hayes TM, Mulligan IP, Kingswood JC, Williams S, Owens DR. How soon after myocardial infarction should plasma lipids be assessed? BMJ 1984; 289: 1651-3.
16. Jackson RT, Beaglehole R. Trends in dietary fat, cigarette smoking and the decline in coronary heart disease in New Zealand. Int J Epidemiol 1987; 16: 377-82.
17. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risk by levels and ratios. Ann Intern Med 1994; 121: 641-7.
18. Slack J. Risks of ischaemic heart disease in familial hyperlipoproteinaemia states. Lancet 1969; 2: 1380-3.
19. Lam K, Cheng IKP, Janus ED, Pang RWC. Cholesterol lowering may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-9.
20. Silberberg JS. Family history of coronary heart disease: a window on disease mechanisms. Lipid Rev 1994; 8: 4-8.
21. Powell KE, Thompson PD, Casperson CJ, Kendrick JS. Physical activity and incidence of coronary heart disease. Ann Rev Public Health 1987; 8: 253-87.
22. Manson JE, Willet CW, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-85.
23. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992; 2: 457-66.
24. Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Ateriosclerosis 1990; 10: 672-9.
25. Graham P, Jackson RT, Beaglehole R, De Boer G. The validity of Maori mortality statistics. NZ Med J 1989; 102: 124-6.
26. Bell C, Swinburn B, Stewart A, Jackson R, Tukuitonga C, Tipene-Leach D. Ethnic differences and recent trends in coronary heart disease incidence in New Zealand. NZ Med J 1996; 109: 66-8.
27. Rivellese AA, Auletta P, Marotta G, et al. Long term metabolic effects of two dietary methods of treating hyperlipidaemia. BMJ 1994; 308: 227-31.
28. Bonanome A, Pagnan A, Biffanti S. Effect of dietary monounsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arteriosclerosis Thrombosis 1992; 12: 529-33.
29. Marckmann P, Sandstrom B, Jeperson J. Favourable long-term effect of a low fat / high fibre diet on human blood coagulation and fibrinolysis. Atherosclerosis Thrombosis 1993; 13: 505-11.
30. Blankenhorn DH, Neseim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
31. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273: 402-7.
32. Adis. New Ethicals Compendium. Auckland: Adis International Ltd, 1995.